SEATTLE, Sept. 3, 2015 /PRNewswire/ -- Faraday Pharmaceuticals today announced the appointment of Stephen A. Hill, M.D., as Chief Executive Officer. Dr. Hill brings extensive experience across multiple facets of biopharmaceutical leadership, clinical development, research and management to Faraday, with leading roles at Targacept, Solvay Pharmaceuticals, ArQule and Roche.
Dr. Hill previously served as CEO and President of Targacept, Inc., a biopharmaceutical company developing a diverse pipeline of NNR Therapeutics. In August 2015 Targacept merged with Catalyst Biosciences Inc. Prior to joining Targacept, Dr. Hill served as President of Solvay Pharmaceuticals, Inc. from 2008 to 2010. Solvay was acquired by Abbott Labs in 2010. From 1999 to 2008, Dr. Hill served as President and CEO of ArQule where he successfully implemented the company's transition from a chemistry services platform to an integrated research and development organization. From 1997 to 1999 Dr. Hill served as Global Head of Clinical Development for Roche Products. He currently serves on the board of directors for publicly held companies Catalyst Biosciences, Cellectar Biosciences, Inc., and Lipocine, Inc. Dr. Hill earned his bachelor and medical degrees from The University of Oxford and practiced medicine in the field of orthopedic surgery prior to his career in the biopharmaceutical industry.
"We are extremely pleased to have Steve join Faraday and know his broad experience and skills will be instrumental as we advance our research and development efforts" said Mark B. Roth, Ph.D., President and Founder of Faraday.
Faraday Pharmaceuticals is a biopharmaceutical company focused on the research and development of elemental reducing agents. These therapeutic agents have potential applications for treatment of critical care illnesses. The company is headquartered in Seattle. For more information, visit www.faradaypharma.com.